CRISM Therapeutics Corporation
CRTX.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -56.4% | – | – | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | £0 | £0 | £0 | £0 |
| % Margin | 84% | 28.9% | – | – |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £1 | £2 | £2 | £1 |
| SG&A Expenses | £1 | £2 | £2 | £1 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£0 | £0 | £0 | £0 |
| Operating Expenses | £1 | £2 | £2 | £1 |
| Operating Income | -£1 | -£2 | -£2 | -£1 |
| % Margin | -2,328% | -3,937.9% | – | – |
| Other Income/Exp. Net | -£0 | £0 | -£0 | -£0 |
| Pre-Tax Income | -£1 | -£2 | -£3 | -£1 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£1 | -£10 | -£2 | -£2 |
| % Margin | -2,428% | -16,816.6% | – | – |
| EPS | -0.1 | -0.068 | -0.28 | -0.18 |
| % Growth | -46.5% | 75.7% | -55.6% | – |
| EPS Diluted | -0.1 | -0.27 | -0.28 | -0.18 |
| Weighted Avg Shares Out | 6 | 9 | 9 | 9 |
| Weighted Avg Shares Out Dil | 6 | 9 | 9 | 9 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | -£0 | £0 | £0 |
| EBITDA | -£1 | -£2 | -£2 | -£1 |
| % Margin | -2,264% | -3,937.9% | – | – |